# FDA 483 - Khaled Tawansy, MD - August 24, 2022

Source: https://www.keypedia.com/records/483/khaled-tawansy-md/b1f65825-1381-4f9e-891c-3b84af3f4ebd

> FDA 483 for Khaled Tawansy, MD on August 24, 2022. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Khaled Tawansy, MD
- Inspection Date: 2022-08-24
- Product Type: drugs
- Office Name: Denver District Office
- Summary: An FDA inspection of Khaled Tawansy, MD, a clinical investigator in Los Angeles, CA, revealed a significant issue regarding the conduct of an investigation. The Principal Investigator failed to provide adequate oversight of study site personnel. This led to uncertified Clinical Research Coordinators performing protocol-specific assessments, which was not in accordance with the investigational plan.

## Related Officers

- [issuing_officer](https://www.keypedia.com/people/ruth-a-williams/f6dd5e30-fe9a-4b18-9703-dc471a55f24f)

Company: https://www.keypedia.com/companies/khaled-tawansy-md/74f11f79-9ae4-42d1-b38f-bc77f4cf1c3c

Office: https://www.keypedia.com/offices/denver-district-office/93b79063-390c-4759-af6c-5da7e388face